Drug intelligence / Profile preview

MSA-2-Pt

Development stage
Preclinical
Lead developer
Nantong University
Modality
Small Molecules
Administration
Intratumoral, Oral
01

Overview

**MSA-2-Pt** is a preclinical platinum salt complex of the non-nucleotide STING agonist MSA-2, developed as a dual-function antitumor small molecule. Its MSA-2 component directly activates stimulator of interferon genes signaling, while its platinum component induces tumor-cell death and the release of damaged DNA, supporting activation of the cGAS-STING innate immune pathway. In published mouse MC38 colon carcinoma and B16F10 melanoma models, intratumoral MSA-2-Pt showed antitumor activity that was modestly greater than MSA-2 alone. It has not been identified as an approved or clinical-stage human therapeutic product. ([europepmc.org](https://europepmc.org/article/MED/38250379))

Other names
CS-0928699CS0928699CS 0928699HY-162133HY162133HY 162133MSA-2 platinum saltMSA2 platinum saltMSA 2 platinum saltMSA-2-PtMSA2-PtMSA 2-PtMSA-2-platinum complexMSA2-platinum complexMSA 2-platinum complexplatinum salt-modified MSA-2
02

Targets

STING (Stimulator of interferon genes protein)DNA

Beyond the preview

Go deeper on MSA-2-Pt.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSA-2-Pt.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call